Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer statistics, 2022
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 72, Iss. 1, pp. 7-33
Open Access | Times Cited: 14398

Showing 51-75 of 14398 citing articles:

Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers
Hyunku Shin, Byeong Hyeon Choi, On Shim, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 150
Emerging phagocytosis checkpoints in cancer immunotherapy
Yue Liu, Yanjin Wang, Yanrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 148
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Guanghe Ran, Yu qing Lin, Lei Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 147
Pharmacological effects and mechanisms of tannic acid
Jing Wang, Xiaolan Chen, Yu Chen, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113561-113561
Open Access | Times Cited: 147
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
Mohamad Dbouk, Bryson W. Katona, Randall E. Brand, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 28, pp. 3257-3266
Open Access | Times Cited: 146
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Nicholas A. Ullman, Paul R. Burchard, Richard F. Dunne, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 24, pp. 2789-2805
Open Access | Times Cited: 145
Transcriptome‐level discovery of survival‐associated biomarkers and therapy targets in non‐small‐cell lung cancer
Balázs Győrffy
British Journal of Pharmacology (2023) Vol. 181, Iss. 3, pp. 362-374
Open Access | Times Cited: 143
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs
Ran Qi, Yixuan Bai, Kun Li, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100960-100960
Open Access | Times Cited: 139
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Raisa A. Glabman, Peter L. Choyke, Noriko Sato
Cancers (2022) Vol. 14, Iss. 16, pp. 3906-3906
Open Access | Times Cited: 137
Multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer therapy: from single to combination therapy
Jie Yang, Dihua Dai, Xi Zhang, et al.
Theranostics (2022) Vol. 13, Iss. 1, pp. 295-323
Open Access | Times Cited: 137
Gas therapy potentiates aggregation-induced emission luminogen-based photoimmunotherapy of poorly immunogenic tumors through cGAS-STING pathway activation
Kaiyuan Wang, Yang Li, Xia Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 135
Carcinogenic components of tobacco and tobacco smoke: A 2022 update
Yupeng Li, Stephen S. Hecht
Food and Chemical Toxicology (2022) Vol. 165, pp. 113179-113179
Open Access | Times Cited: 134
Screening for lung cancer: 2023 guideline update from the American Cancer Society
Andrew M. D. Wolf, Kevin C. Oeffinger, Ya‐Chen Tina Shih, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 1, pp. 50-81
Open Access | Times Cited: 133
Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer
Daniel Cui Zhou, Reyka G. Jayasinghe, Siqi Chen, et al.
Nature Genetics (2022) Vol. 54, Iss. 9, pp. 1390-1405
Open Access | Times Cited: 132
Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges
Chunyan Duan, Mingjia Yu, Jiyuan Xu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114643-114643
Open Access | Times Cited: 130
Principles and methods for transferring polygenic risk scores across global populations
Linda Kachuri, Nilanjan Chatterjee, Jibril Hirbo, et al.
Nature Reviews Genetics (2023) Vol. 25, Iss. 1, pp. 8-25
Open Access | Times Cited: 129
Epidemiology of Thyroid Cancer
Cari M. Kitahara, Arthur B. Schneider
Cancer Epidemiology Biomarkers & Prevention (2022) Vol. 31, Iss. 7, pp. 1284-1297
Open Access | Times Cited: 128
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 3, pp. 283-299
Open Access | Times Cited: 125
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Maoping Cai, Xian‐Lu Song, Xinan Li, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100962-100962
Open Access | Times Cited: 122
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Manish A. Shah, Erin B. Kennedy, Ashley E. Alarcon-Rozas, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 7, pp. 1470-1491
Open Access | Times Cited: 121
Bioactive inorganic nanomaterials for cancer theranostics
Zifan Pei, Huali Lei, Liang Cheng
Chemical Society Reviews (2023) Vol. 52, Iss. 6, pp. 2031-2081
Closed Access | Times Cited: 120
Clinical and translational advances in ovarian cancer therapy
Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Nature Cancer (2023) Vol. 4, Iss. 9, pp. 1239-1257
Closed Access | Times Cited: 120
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 118
Air pollution: A culprit of lung cancer
Yueguang Xue, Liuxiang Wang, Yiming Zhang, et al.
Journal of Hazardous Materials (2022) Vol. 434, pp. 128937-128937
Closed Access | Times Cited: 117
Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Chen Fu, Lifeng Yu, Yuxi Miao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 2, pp. 498-516
Open Access | Times Cited: 111

Scroll to top